RWE(Real World Evidence) 솔루션 시장 규모, 점유율 및 동향 분석 보고서 : 컴포넌트별, 용도별, 최종 용도별, 치료 영역별, 지역별, 부문 예측(2025-2033년)
Real World Evidence Solutions Market Size, Share & Trends Analysis Report By Component, By Application, By End Use, By Therapeutic Area, By Region, And Segment Forecasts, 2025 - 2033
상품코드:1888812
리서치사:Grand View Research
발행일:2025년 11월
페이지 정보:영문 190 Pages
라이선스 & 가격 (부가세 별도)
ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
한글목차
RWE(Real World Evidence) 솔루션 시장 요약
세계의 RWE(Real World Evidence) 솔루션 시장 규모는 2024년에 28억 1,000만 달러로 추정되며, 2033년까지 60억 1,000만 달러에 이를 것으로 예측됩니다.
또한 2025년부터 2033년까지 연평균 복합 성장률(CAGR) 8.94%를 보일 것으로 예측됩니다. 이러한 성장은 R&D 비용 증가, 다양한 분야에서의 RWE(Real World Evidence) 적용 확대, RWE 솔루션의 활용에 대한 규제 당국의 지원, 그리고 실제 데이터 양 증가가 시장 성장을 가속할 것으로 예상되기 때문입니다.
규제 측면에서의 리얼월드 증거의 수용성 확대는 시장 확대의 주요 촉진요인으로, 세계 각국의 규제 기관이 리얼월드 데이터(RWD)가 승인, 적응증 확대, 시판 후 판단에 도움을 줄 수 있는 시기와 방법에 대해 보다 명확한 규칙을 제공하고 있는 것이 그 배경입니다. 이러한 명확성은 컴플라이언스에 대한 불확실성을 줄이고, 제약 및 생명공학 기업들이 강력한 실제 데이터 플랫폼에 대한 투자를 촉진하고 있습니다. 실제 데이터 활용을 가능하게 하는 주요 규제 이니셔티브에는 다음과 같은 것들이 있습니다.
강력한 RWE 플랫폼에 대한 투자를 독려하고 있습니다. RWE 도입을 가능하게 하는 주요 규제 이니셔티브는 다음과 같습니다.
FDA(미국) - 21세기 치료법(21st Century Cures Act) 및 전용 RWE 지침을 통해 FDA는 전자건강기록(EHR), 보험 청구 데이터, 레지스트리 데이터가 규제 신청에 어떻게 도움이 될 수 있는지, 그리고 데이터 품질과 연구 방법을 어떻게 검증해야 하는지를 명확히 정의합니다. 명확하게 정의하고 있습니다.
EMA(유럽) - EMA의 DARWIN EU 네트워크, RWE 로드맵, 데이터 품질 프레임워크는 유럽 전역에서 RWD의 사용을 표준화하고 RWE를 라이프사이클 평가에 일관성 있게 통합할 수 있도록 합니다.
MHRA(영국) - MHRA는 RWD 기반 연구 및 RWD를 사용한 RCT에 대한 실질적인 지침을 제공하고, 허용되는 데이터 소스, 엔드포인트, 안전 프로세스를 개괄적으로 설명합니다. 이는 RWE의 RWE 과학 대화 프로세스에 의해 지원되고 있습니다.
PMDA(일본) - PMDA는 특히 희귀질환 및 소아질환에서 승인 및 표시 갱신을 위해 레지스트리 기반 증거를 점점 더 많이 수용하는 한편, 강력한 데이터 신뢰성과 분석의 정확성을 중요시하고 있습니다.
이러한 규제 당국의 노력은 업계에서 실세계 증거 방법에 대한 신뢰를 높이고, RWE 솔루션의 세계 확산을 촉진하고 있습니다.
건강 관련 데이터의 양이 매년 36%씩 증가하고 있는 가운데, 실세계 데이터의 양이 증가하고 있는 것이 RWE(Real World Evidence) 솔루션 시장의 주요 촉진요인으로 작용하고 있습니다. 전자 건강 기록, 보험 청구 데이터, 질병 레지스트리, 웨어러블 기기, 환자 보고 결과(PRO)의 데이터는 규모와 상세도 측면에서 증가하고 있습니다. 데이터 통합, 상호운용성, 분석 기술의 발전으로 RWE 플랫폼은 이러한 방대한 데이터 세트를 의미 있고 실행 가능한 인사이트으로 전환할 수 있게 되었습니다. 이를 통해 제약사, 지불자, 의료 서비스 제공업체는 보다 정확하고 대표성 있고 시의적절한 근거를 생성할 수 있으며, 의약품 개발, 규제 당국 신청, 가치 기반 의료(Value-Based Care) 노력을 지원할 수 있습니다.
목차
제1장 조사 방법과 범위
제2장 주요 요약
제3장 리아르워르드에비덴스 솔루션 시장 변수, 동향 및 범위
시장 계통 전망
관련 시장 및 부수 시장 전망
시장 역학
사례 연구 지견
사례 연구 1 : 리아르워르드에비덴스가 적응 확대 규제 경로를 가능하게
사례 연구 2
사례 연구 3
사례 연구 4
사례 연구 5
RWE(Real World Evidence) 솔루션 시장 분석 툴
업계 분석 - Porter의 Five Forces 분석
PESTEL 분석
가격 모델 분석
제4장 RWE(Real World Evidence) 솔루션 시장 : 컴포넌트별, 추정 및 동향 분석
세계의 RWE(Real World Evidence) 솔루션 시장 : 컴포넌트 대시보드
세계의 RWE(Real World Evidence) 솔루션 시장 : 컴포넌트별 변동 분석
세계의 RWE(Real World Evidence) 솔루션 시장 : 컴포넌트별, 매출
서비스
데이터 세트 시스템
임상 설정 데이터
청구 데이터
약국 데이터
환자 주도 데이터
제5장 RWE(Real World Evidence) 솔루션 시장 : 용도별, 추정 및 동향 분석
세계의 RWE(Real World Evidence) 솔루션 시장 : 용도 대시보드
세계의 RWE(Real World Evidence) 솔루션 시장 : 용도 변동 분석
세계의 RWE(Real World Evidence) 솔루션 시장 추정·예측 : 용도별, 매출별
의약품 개발 및 승인
의료기기 개발 및 승인
상환/보험 적용 범위 및 규제상 의사결정
시판 후 안전성 및 유해사례 모니터링
제6장 RWE(Real World Evidence) 솔루션 시장 : 최종 용도별, 추정 및 동향 분석
세계의 RWE(Real World Evidence) 솔루션 시장 : 최종 용도 대시보드
세계의 RWE(Real World Evidence) 솔루션 시장 : 최종 용도 변동 분석
세계의 RWE(Real World Evidence) 솔루션 시장 추산·예측 : 최종 용도별, 매출별
헬스케어 기업(제약, 바이오의약품, 의료기기)
임상 연구
감독하 상업(마케팅 등 포함)
HEOR
기타(시장 접근 등)
의료보험자용 업무 처리
의료 제공업체
기타
제7장 RWE(Real World Evidence) 솔루션 시장 : 치료 영역별, 추정 및 동향 분석
세계의 RWE(Real World Evidence) 솔루션 시장 : 치료 영역 대시보드
세계의 RWE(Real World Evidence) 솔루션 시장 : 치료 영역별 변동 분석
세계의 RWE(Real World Evidence) 솔루션 시장 추정·예측 : 치료 영역별, 매출
종양학
심장병학
신경학
정신의학
호흡기
기타 치료 영역(면역학, 소화기학 등)
제8장 RWE(Real World Evidence) 솔루션 시장 : 지역별, 추정·동향 분석(컴포넌트, 용도, 최종 용도, 치료 영역별)
지역별 대시보드
시장 규모 및 예측, 동향 분석, 2021년-2033년 :
북미
미국
캐나다
멕시코
유럽
영국
독일
프랑스
이탈리아
스페인
덴마크
스웨덴
노르웨이
아시아태평양
일본
중국
인도
한국
태국
호주
라틴아메리카
브라질
아르헨티나
중동 및 아프리카
남아프리카공화국
사우디아라비아
이스라엘
아랍에미리트(UAE)
쿠웨이트
제9장 경쟁 구도
기업 시장 현황 분석/기업 점유율 분석(2024년)
기업 분류
전략 매핑
기업 개요/상장기업 리스트
IQVIA
Merative
PPD Inc.(now part of Thermo Fisher)
Parexel International Corporation
Icon Plc
Oracle
Syneos Health
Cegedim Health Data
Medpace
Optum Inc.(UnitedHealth Group)
SAS Institute Inc.
Cognizant
Aetion, Inc.(acquired by Datavant in May 2025)
Flatiron Health
Cytel Inc.
Trinity
NTT Data Inc.
LSH
영문 목차
영문목차
Real World Evidence Solutions Market Summary
The global real world evidence solutions market size was estimated at USD 2.81 billion in 2024 and is projected to reach USD 6.01 billion by 2033, growing at a CAGR of 8.94% from 2025 to 2033. This growth is attributed to the increase in R&D spending, rising applications of real-world evidence (RWE) in various fields, support from regulatory bodies for using real world evidence (RWE) solutions and growing volume of real-world data are anticipated to boost the market growth.
Growing regulatory acceptance of real-world evidence is a major driving factor for market expansion, as global agencies now provide clearer rules on when and how RWD can support approvals, label expansions, and post-market decisions. This increasing clarity reduces compliance uncertainty and motivates pharma and biotech to invest
FDA (U.S.) - Through the 21st Century Cures Act and dedicated RWE guidance, the FDA clearly defines how EHR, claims, and registry data can support regulatory submissions and how data quality and methodologies should be validated.
EMA (EU) - EMA's DARWIN EU network, RWE Roadmap, and Data Quality Framework standardize RWD use across Europe, enabling consistent integration of RWE into lifecycle assessments.
MHRA (UK) - MHRA provides practical guidance on RWD-based studies and RCTs using RWD, outlining acceptable sources, endpoints, and safety processes, supported by its RWE Scientific Dialogue pathway.
PMDA (Japan) - PMDA emphasizes strong data reliability and analytic accuracy while increasingly accepting registry-based evidence for approvals and label updates, especially in rare and pediatric conditions.
Such regulatory efforts are strengthening industry's trust in real-world evidence approaches, thereby driving broader global uptake of RWE solutions.
The growing volume of real-world data is a key driver for the Real-World Evidence (RWE) solutions market, as the volume of health-related data continues to grow at a compound annual rate of 36%. Data from electronic health records, insurance claims, disease registries, wearables, and patient-reported outcomes is increasing in both scale and granularity. Advances in data integration, interoperability, and analytics enable RWE platforms to transform these vast datasets into meaningful, actionable insights. This allows pharmaceutical companies, payers, and healthcare providers to generate more accurate, representative, and timely evidence, supporting drug development, regulatory submissions, and value-based care initiatives.
Global Real World Evidence Solutions Market Report Segmentation
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global real world evidence solutions market report based on component, application, end use, therapeutic area, and region.
Component Outlook (Revenue, USD Million, 2021 - 2033)
Services
Data Sets
Clinical Settings Data
Claims Data
Pharmacy Data
Patient-Powered Data
Application Outlook (Revenue, USD Million, 2021 - 2033)
Drug Development & Approvals
Medical Device Development & Approvals
Reimbursement/Coverage and Regulatory Decision Making
Post Market Safety & Adverse Events Monitoring
End Use Outlook (Revenue, USD Million, 2021 - 2033)
Healthcare Companies (Pharmaceutical, Biopharmaceutical, Medical Device)
Clinical research
Commercial (inclusive of marketing, etc.)
HEOR
Others (market access, etc.)
Healthcare Payers
Healthcare Providers
Others
Therapeutic Area Outlook (Revenue, USD Million, 2021 - 2033)
Oncology
Cardiology
Neurology
Diabetes
Psychiatry
Respiratory
Other Therapeutic Areas (Immunology, Gastroenterology, etc.)
Regional Outlook (Revenue, USD Million, 2021 - 2033)
North America
U.S.
Canada
Mexico
Europe
UK
Germany
France
Italy
Spain
Denmark
Sweden
Norway
Asia Pacific
China
Japan
India
South Korea
Australia
Thailand
Latin America
Brazil
Argentina
Middle East and Africa (MEA)
South Africa
Saudi Arabia
UAE
Kuwait
Table of Contents
Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.2. Segment Definitions
1.2.1. Component
1.2.2. Application
1.2.3. End Use
1.2.4. Therapeutic Area
1.2.5. Regional scope
1.2.6. Estimates and forecasts timeline
1.3. Research Methodology
1.4. Information Procurement
1.4.1. Purchased database
1.4.2. GVR's internal database
1.4.3. Secondary sources
1.4.4. Primary research
1.4.5. Details of primary research
1.5. Information or Data Analysis
1.5.1. Data analysis models
1.6. Market Formulation & Validation
1.7. Model Details
1.7.1. Commodity flow analysis
1.8. List of Secondary Sources
1.9. List of Primary Sources
1.10. Objectives
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.2.1. Component and Application outlook
2.2.2. End use and Therapeutic Area outlook
2.2.3. Regional outlook
2.3. Competitive Insights
Chapter 3. Real World Evidence Solutions Market Variables, Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Related/ancillary market outlook
3.2. Market Dynamics
3.2.1. Market driver analysis
3.2.1.1. Regulatory Support for RWE Integration
3.2.1.2. Rising Demand for Cost-effective Drug Development
3.2.1.3. Growing Volume of Real-World Data
3.2.1.4. Increasing Use of RWE in Clinical Trial Design
3.2.1.5. Growing Emphasis on Personalized Medicine
3.2.1.6. Strategic Collaborations Between Stakeholders
3.2.1.7. Growing Demand for Drug Safety and Post-Market Surveillance
3.2.1.8. Expansion of Healthcare Data Sources
3.2.2. Market restraint analysis
3.2.2.1. Lack of Access to Data
3.2.2.2. Data privacy concerns
3.2.2.3. Data Quality, Completeness, and Standardization Issues
3.2.2.4. Regulatory Compliance Challenges
3.2.3. Market Opportunity analysis
3.2.4. Market Challenges analysis
3.3. Case Study Insights
3.3.1. Case Study 1: Real-World Evidence Enables Regulatory Pathway for Label Expansion
3.3.2. Case Study 2
3.3.3. Case Study 3
3.3.4. Case Study 4
3.3.5. Case Study 5
3.4. Real World Evidence Solutions Market Analysis Tools
3.4.1. Industry Analysis - Porter's Five Forces Analysis
3.4.1.1. Supplier power
3.4.1.2. Buyer power
3.4.1.3. Substitution threat
3.4.1.4. Threat of new entrant
3.4.1.5. Competitive rivalry
3.4.2. PESTEL Analysis
3.4.2.1. Political
3.4.2.2. Economic
3.4.2.3. Social
3.4.2.4. Technological
3.4.2.5. Environmental
3.4.2.6. Legal
3.4.3. Pricing Model Analysis
3.4.3.1. As per usage
3.4.3.2. Pay per patient record
3.4.3.3. Annual/monthly subscription
Chapter 4. Real World Evidence Solutions Market: Component Estimates & Trend Analysis
4.1. Global Real World Evidence Solutions Market: Component Dashboard
4.2. Global Real World Evidence Solutions Market: Component Movement Analysis
4.3. Global Real World Evidence Solutions Market by Component, Revenue (USD Million)
4.4. Services
4.4.1. Services market estimates and forecasts 2021 to 2033 (USD Million)
4.5. Data sets Systems
4.5.1. Multi agent systems market estimates and forecasts 2021 to 2033 (USD Million)
4.5.2. Clinical Settings Data
4.5.2.1. Clinical Settings Data market estimates and forecasts 2021 to 2033 (USD Million)
4.5.3. Claims Data
4.5.3.1. Claims Data market estimates and forecasts 2021 to 2033 (USD Million)
4.5.4. Pharmacy Data
4.5.4.1. Pharmacy Data market estimates and forecasts 2021 to 2033 (USD Million)
4.5.5. Patient-Powered Data
4.5.5.1. Patient Powered Data market estimates and forecasts 2021 to 2033 (USD Million)
Chapter 5. Real World Evidence Solutions Market: Application Estimates & Trend Analysis
5.1. Global Real World Evidence Solutions Market: Application Dashboard
5.2. Global Real World Evidence Solutions Market: Application Movement Analysis
5.3. Global Real World Evidence Solutions Market Estimates and Forecasts, By Application, Revenue (USD Million)
5.4. Drug Development & Approvals
5.4.1. Drug development & approval market estimates and forecasts 2021 to 2033 (USD Million)
5.5. Medical Device Development & Approvals
5.5.1. Medical device development & approvals market estimates and forecasts 2021 to 2033 (USD Million)
5.6. Reimbursement/Coverage and Regulatory Decision Making
5.6.1. Reimbursement/Coverage and Regulatory Decision Making market estimates and forecasts 2021 to 2033 (USD Million)
5.7. Post Market Safety & Adverse Events Monitoring
5.7.1. Post Market Safety & Adverse Events Monitoring market estimates and forecasts 2021 to 2033 (USD Million)
Chapter 6. Real World Evidence Solutions Market: End Use Estimates & Trend Analysis
6.1. Global Real World Evidence Solutions Market: End Use Dashboard
6.2. Global Real World Evidence Solutions Market: End Use Movement Analysis
6.3. Global Real World Evidence Solutions Market Estimates and Forecasts, By End Use, Revenue (USD Million)
6.4. Healthcare Companies (Pharmaceutical, Biopharmaceutical, Medical Device)
6.4.1. Healthcare Companies (Pharmaceutical, Biopharmaceutical, Medical Device) market estimates and forecasts 2021 to 2033 (USD Million)
6.4.2. Clinical research
6.4.2.1. Clinical research market estimates and forecasts 2021 to 2033 (USD Million)
6.4.3. Supervised Commercial (inclusive of marketing, etc.)
6.4.3.1. Commercial (inclusive of marketing, etc.) market estimates and forecasts 2021 to 2033 (USD Million)
6.4.4. HEOR
6.4.4.1. HEOR market estimates and forecasts 2021 to 2033 (USD Million)
6.4.5. Others (market access, etc.)
6.4.5.1. Others (market access, etc.) market estimates and forecasts 2021 to 2033 (USD Million)
6.5. Processing Healthcare Payers
6.5.1. Healthcare Payers market estimates and forecasts 2021 to 2033 (USD Million)
6.5.2. Healthcare Providers
6.5.2.1. Healthcare Providers market estimates and forecasts 2021 to 2033 (USD Million)
6.5.3. Others
6.5.3.1. Others market estimates and forecasts 2021 to 2033 (USD Million)
Chapter 7. Real World Evidence Solutions Market: Therapeutic Area Estimates & Trend Analysis
7.1. Global Real World Evidence Solutions Market: Therapeutic Area Dashboard
7.2. Global Real World Evidence Solutions Market: Therapeutic Area Movement Analysis
7.3. Global Real World Evidence Solutions Market Estimates and Forecasts, By Therapeutic Area, Revenue (USD Million)
7.4. Oncology
7.4.1. Oncology market estimates and forecasts 2021 to 2033 (USD Million)
7.5. Cardiology
7.5.1. Cardiology market estimates and forecasts 2021 to 2033 (USD Million)
7.6. Neurology
7.6.1. Neurology market estimates and forecasts 2021 to 2033 (USD Million)
7.7. Psychiatry
7.7.1. Psychiatry market estimates and forecasts 2021 to 2033 (USD Million)
7.8. Respiratory
7.8.1. Respiratory market estimates and forecasts 2021 to 2033 (USD Million)
7.9. Other Therapeutic Areas (Immunology, Gastroenterology, etc.)
7.9.1. Other Therapeutic Areas (Immunology, Gastroenterology, etc.) market estimates and forecasts 2021 to 2033 (USD Million)
Chapter 8. Real World Evidence Solutions Market: Regional Estimates & Trend Analysis by Component, Application, End use, and Therapeutic Area
8.1. Regional Dashboard
8.2. Market Size, & Forecasts Trend Analysis, 2021 to 2033:
8.3. North America
8.3.1. U.S.
8.3.1.1. Key country dynamics
8.3.1.2. Regulatory framework
8.3.1.3. Competitive scenario
8.3.1.4. U.S. market estimates and forecasts 2021 to 2033 (USD Million)
8.3.2. Canada
8.3.2.1. Key country dynamics
8.3.2.2. Regulatory framework
8.3.2.3. Competitive scenario
8.3.2.4. Canada market estimates and forecasts 2021 to 2033 (USD Million)
8.3.3. Mexico
8.3.3.1. Key country dynamics
8.3.3.2. Regulatory framework
8.3.3.3. Competitive scenario
8.3.3.4. Mexico market estimates and forecasts 2021 to 2033 (USD Million)
8.4. Europe
8.4.1. UK
8.4.1.1. Key country dynamics
8.4.1.2. Regulatory framework
8.4.1.3. Competitive scenario
8.4.1.4. UK market estimates and forecasts 2021 to 2033 (USD Million)
8.4.2. Germany
8.4.2.1. Key country dynamics
8.4.2.2. Regulatory framework
8.4.2.3. Competitive scenario
8.4.2.4. Germany market estimates and forecasts 2021 to 2033 (USD Million)
8.4.3. France
8.4.3.1. Key country dynamics
8.4.3.2. Regulatory framework
8.4.3.3. Competitive scenario
8.4.3.4. France market estimates and forecasts 2021 to 2033 (USD Million)
8.4.4. Italy
8.4.4.1. Key country dynamics
8.4.4.2. Regulatory framework
8.4.4.3. Competitive scenario
8.4.4.4. Italy market estimates and forecasts 2021 to 2033 (USD Million)
8.4.5. Spain
8.4.5.1. Key country dynamics
8.4.5.2. Regulatory framework
8.4.5.3. Competitive scenario
8.4.5.4. Spain market estimates and forecasts 2021 to 2033 (USD Million)
8.4.6. Denmark
8.4.6.1. Key country dynamics
8.4.6.2. Regulatory framework
8.4.6.3. Competitive scenario
8.4.6.4. Denmark market estimates and forecasts 2021 to 2033 (USD Million)
8.4.7. Sweden
8.4.7.1. Key country dynamics
8.4.7.2. Regulatory framework
8.4.7.3. Competitive scenario
8.4.7.4. Sweden market estimates and forecasts 2021 to 2033 (USD Million)
8.4.8. Norway
8.4.8.1. Key country dynamics
8.4.8.2. Regulatory framework
8.4.8.3. Competitive scenario
8.4.8.4. Norway market estimates and forecasts 2021 to 2033 (USD Million)
8.5. Asia Pacific
8.5.1. Japan
8.5.1.1. Key country dynamics
8.5.1.2. Regulatory framework
8.5.1.3. Competitive scenario
8.5.1.4. Japan market estimates and forecasts 2021 to 2033 (USD Million)
8.5.2. China
8.5.2.1. Key country dynamics
8.5.2.2. Regulatory framework
8.5.2.3. Competitive scenario
8.5.2.4. China market estimates and forecasts 2021 to 2033 (USD Million)
8.5.3. India
8.5.3.1. Key country dynamics
8.5.3.2. Regulatory framework
8.5.3.3. Competitive scenario
8.5.3.4. India market estimates and forecasts 2021 to 2033 (USD Million)
8.5.4. South Korea
8.5.4.1. Key country dynamics
8.5.4.2. Regulatory framework
8.5.4.3. Competitive scenario
8.5.4.4. South Korea market estimates and forecasts 2021 to 2033 (USD Million)
8.5.5. Thailand
8.5.5.1. Key country dynamics
8.5.5.2. Regulatory framework
8.5.5.3. Competitive scenario
8.5.5.4. Thailand market estimates and forecasts 2021 to 2033 (USD Million)
8.5.6. Australia
8.5.6.1. Key country dynamics
8.5.6.2. Regulatory framework
8.5.6.3. Competitive scenario
8.5.6.4. Australia market estimates and forecasts 2021 to 2033 (USD Million)
8.6. Latin America
8.6.1. Brazil
8.6.1.1. Key country dynamics
8.6.1.2. Regulatory framework
8.6.1.3. Competitive scenario
8.6.1.4. Brazil market estimates and forecasts 2021 to 2033 (USD Million)
8.6.2. Argentina
8.6.2.1. Key country dynamics
8.6.2.2. Regulatory framework
8.6.2.3. Competitive scenario
8.6.2.4. Argentina market estimates and forecasts 2021 to 2033 (USD Million)
8.7. MEA
8.7.1. South Africa
8.7.1.1. Key country dynamics
8.7.1.2. Regulatory framework
8.7.1.3. Competitive scenario
8.7.1.4. South Africa market estimates and forecasts 2021 to 2033 (USD Million)
8.7.2. Saudi Arabia
8.7.2.1. Key country dynamics
8.7.2.2. Regulatory framework
8.7.2.3. Competitive scenario
8.7.2.4. Saudi Arabia market estimates and forecasts 2021 to 2033 (USD Million)
8.7.3. Israel
8.7.3.1. Key country dynamics
8.7.3.2. Regulatory framework
8.7.3.3. Competitive scenario
8.7.3.4. Israel market estimates and forecasts 2021 to 2033 (USD Million)
8.7.4. UAE
8.7.4.1. Key country dynamics
8.7.4.2. Regulatory framework
8.7.4.3. Competitive scenario
8.7.4.4. UAE market estimates and forecasts 2021 to 2033 (USD Million)
8.7.5. Kuwait
8.7.5.1. Key country dynamics
8.7.5.2. Regulatory framework
8.7.5.3. Competitive scenario
8.7.5.4. Kuwait market estimates and forecasts 2021 to 2033 (USD Million)
Chapter 9. Competitive Landscape
9.1. Company Market Position Analysis/ Company Market Share Analysis, 2024
9.2. Company Categorization
9.3. Strategy Mapping
9.4. Company Profiles/Listing
9.4.1. IQVIA
9.4.1.1. Overview
9.4.1.2. Financial performance
9.4.1.3. Product benchmarking
9.4.1.4. Strategic initiatives
9.4.2. Merative
9.4.2.1. Overview
9.4.2.2. Financial performance
9.4.2.3. Product benchmarking
9.4.2.4. Strategic initiatives
9.4.3. PPD Inc. (now part of Thermo Fisher)
9.4.3.1. Overview
9.4.3.2. Financial performance
9.4.3.3. Product benchmarking
9.4.3.4. Strategic initiatives
9.4.4. Parexel International Corporation
9.4.4.1. Overview
9.4.4.2. Financial performance
9.4.4.3. Product benchmarking
9.4.4.4. Strategic initiatives
9.4.5. Icon Plc
9.4.5.1. Overview
9.4.5.2. Financial performance
9.4.5.3. Product benchmarking
9.4.5.4. Strategic initiatives
9.4.6. Oracle
9.4.6.1. Overview
9.4.6.2. Financial performance
9.4.6.3. Product benchmarking
9.4.6.4. Strategic initiatives
9.4.7. Syneos Health
9.4.7.1. Overview
9.4.7.2. Financial performance
9.4.7.3. Product benchmarking
9.4.7.4. Strategic initiatives
9.4.8. Cegedim Health Data
9.4.8.1. Overview
9.4.8.2. Financial performance
9.4.8.3. Product benchmarking
9.4.8.4. Strategic initiatives
9.4.9. Medpace
9.4.9.1. Overview
9.4.9.2. Financial performance
9.4.9.3. Product benchmarking
9.4.9.4. Strategic initiatives
9.4.10. Optum Inc. (UnitedHealth Group)
9.4.10.1. Overview
9.4.10.2. Financial performance
9.4.10.3. Product benchmarking
9.4.10.4. Strategic initiatives
9.4.11. SAS Institute Inc.
9.4.11.1. Overview
9.4.11.2. Financial performance
9.4.11.3. Product benchmarking
9.4.11.4. Strategic initiatives
9.4.12. Cognizant
9.4.12.1. Overview
9.4.12.2. Financial performance
9.4.12.3. Product benchmarking
9.4.12.4. Strategic initiatives
9.4.13. Aetion, Inc. (acquired by Datavant in May 2025)
